First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
- 17 May 2022
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (20) , 2521-2532
Abstract
Aim: To compare the overall survival (OS) among patients who received first-line modified gemcitabine plus nab-paclitaxel (G/nab-P) or 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFI... Plain language summary Pancreatic cancer that has spread to other parts of the body cannot be cured and patients usually have a limited time to live after diagnosis. It is therefore important to ch...Keywords
Funding Information
- Ohio State University (UL1TR001070)
This publication has 24 references indexed in Scilit:
- Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407)Pancreatology, 2018
- Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United StatesAdvances in Therapy, 2018
- Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2018
- Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patientsClinica Chimica Acta, 2018
- Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community settingCancer Management and Research, 2017
- A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysisTherapeutic Advances in Medical Oncology, 2016
- Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the PancreasAnnals of Surgical Oncology, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009